title: Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
abstract: Gemifloxacin is a novel fluoronaphthyridone quinolone with enhanced in vitro activity against Streptococcus pneumoniae. We investigated the activities of gemifloxacin and trovafloxacin, their abilities to select for resistance in vitro and in vivo, and their efficacies in a mouse model of acute pneumonia. Immunocompetent Swiss mice were infected with 10(5) CFU of a virulent, encapsulated S. pneumoniae strain, P-4241, or its isogenic parC, gyrA, parC gyrA, and efflux mutant derivatives (serotype 3); and leukopenic mice were infected with 10(7) CFU of two poorly virulent clinical strains (serotype 11A) carrying either a parE mutation or a parC, gyrA, and parE triple mutation. The drugs were administered six times every 12 h, starting at either 3 or 18 h postinfection. In vitro, gemifloxacin was the most potent agent against strains with and without acquired resistance to fluoroquinolones. While control mice died within 6 days, gemifloxacin at doses of 25 and 50 mg/kg of body weight was highly effective (survival rates, 90 to 100%) against the wild-type strain and against mutants harboring a single mutation, corresponding to area under the time-versus-serum concentration curve at 24 h (AUC(24))/MIC ratios of 56.5 to 113, and provided a 40% survival rate against a mutant with a double mutation (parC and gyrA). A total AUC(24)/MIC ratio of 28.5 was associated with poor efficacy and the emergence of resistant mutants. Trovafloxacin was as effective as gemifloxacin against mutants with single mutations but did not provide any protection against the mutant with double mutations, despite treatment with a high dose of 200 mg/kg. Gemifloxacin preferentially selected for parC mutants both in vitro and in vivo.
authors.affiliation: INSERM EMI-U 9933, Faculté Xavier Bichat, 16, rue Henri Huchard, 75870 Paris Cedex 18, France. eazoulay@bichat.inserm.fr
authors.forename: E
authors.initials: E
authors.lastname: Azoulay-Dupuis
authors.forename: J P
authors.initials: JP
authors.lastname: Bédos
authors.forename: J
authors.initials: J
authors.lastname: Mohler
authors.forename: P
authors.initials: P
authors.lastname: Moine
authors.forename: C
authors.initials: C
authors.lastname: Cherbuliez
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
authors.forename: B
authors.initials: B
authors.lastname: Fantin
authors.forename: T
authors.initials: T
authors.lastname: Köhler
mesh_terms: D000818:Animals; D019540:Area Under Curve; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077735:Gemifloxacin; D051379:Mice; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009287:Naphthyridines / Q000493:pharmacokinetics / Q000494:pharmacology*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics
chemical_list: D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:23-7
references.pmid: 10824028
references.citation: Antimicrob Agents Chemother. 2000 Feb;44(2):304-10
references.pmid: 10639354
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:41-6
references.pmid: 10824031
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:95-9
references.pmid: 10824039
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:107-10
references.pmid: 10824041
references.citation: J Antimicrob Chemother. 1999 Nov;44(5):679-88
references.pmid: 10552986
references.citation: Antimicrob Agents Chemother. 1999 Dec;43(12):2998-3000
references.pmid: 10582896
references.citation: Antimicrob Agents Chemother. 2000 Jun;44(6):1604-8
references.pmid: 10817716
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:1-12
references.pmid: 10824026
references.citation: Clin Infect Dis. 2000 Aug;31(2):347-82
references.pmid: 10987697
references.citation: Antimicrob Agents Chemother. 2000 Nov;44(11):2962-8
references.pmid: 11036007
references.citation: Antimicrob Agents Chemother. 2000 Nov;44(11):3112-7
references.pmid: 11036032
references.citation: Antimicrob Agents Chemother. 2001 Mar;45(3):938-42
references.pmid: 11181385
references.citation: J Antimicrob Chemother. 2001 Sep;48(3):365-74
references.pmid: 11533001
references.citation: Antimicrob Agents Chemother. 2001 Oct;45(10):2793-7
references.pmid: 11557471
references.citation: J Antimicrob Chemother. 2002 Jun;49(6):1015-8
references.pmid: 12039895
references.citation: Microb Drug Resist. 2002 Summer;8(2):79-84
references.pmid: 12118521
references.citation: J Antimicrob Chemother. 2002 Oct;50(4):495-502
references.pmid: 12356793
references.citation: Antimicrob Agents Chemother. 2003 Jan;47(1):440-1
references.pmid: 12499234
references.citation: Clin Infect Dis. 2003 Nov 1;37(9):1210-5
references.pmid: 14557966
references.citation: Antimicrob Agents Chemother. 2004 Mar;48(3):765-73
references.pmid: 14982762
references.citation: Clin Infect Dis. 1992 Jul;15(1):77-83
references.pmid: 1617076
references.citation: Antimicrob Agents Chemother. 1992 Dec;36(12):2698-703
references.pmid: 1336343
references.citation: Antimicrob Agents Chemother. 1993 May;37(5):1073-81
references.pmid: 8517694
references.citation: Chest. 1994 May;105(5):1487-95
references.pmid: 8181342
references.citation: N Engl J Med. 1995 Aug 24;333(8):474-80
references.pmid: 7623879
references.citation: Thorax. 1996 Feb;51(2):179-84
references.pmid: 8711652
references.citation: Drugs. 1996;51 Suppl 1:1-5
references.pmid: 8724810
references.citation: Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7
references.pmid: 8891124
references.citation: Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4
references.pmid: 9124836
references.citation: Antimicrob Agents Chemother. 1997 Feb;41(2):471-4
references.pmid: 9021211
references.citation: Antimicrob Agents Chemother. 1997 Sep;41(9):1973-8
references.pmid: 9303396
references.citation: Antimicrob Agents Chemother. 1998 Apr;42(4):862-7
references.pmid: 9559797
references.citation: Antimicrob Agents Chemother. 1998 Aug;42(8):2032-5
references.pmid: 9687402
references.citation: Antimicrob Agents Chemother. 1998 Nov;42(11):2956-60
references.pmid: 9797232
references.citation: Antimicrob Agents Chemother. 1999 Jan;43(1):187-9
references.pmid: 9869592
references.citation: N Engl J Med. 1999 Jul 22;341(4):233-9
references.pmid: 10413735
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl 1:29-33
references.pmid: 10824029